A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis
This clinical trial aims to evaluate the efficacy of cisplatin alone versus cisplatin combined with gemcitabine in patients with carcinoma of unknown primary and a favorable prognosis. The study is sponsored by Gustave Roussy, Cancer Campus, Grand Paris, and is currently recruiting participants.
Indication: Carcinoma
Modality: small molecule
Target: Carcinoma of Unknown Primary (CUP)
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Source URL: ClinicalTrials.gov
Source updated: Sep 08, 2006
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Carcinoma of Unknown Primary (CUP)
View original source fields
Condition raw: Carcinoma
Condition normalized: Carcinoma
Modality raw: Carcinoma
Modality normalized: small molecule
Target raw: Carcinoma of Unknown Primary (CUP)
Target normalized: Carcinoma of Unknown Primary (CUP)